Abstract
Background and purpose: To evaluate the results of low-dose radiation therapy (LD-RT) to lungs in the management of patients with COVID-19 pneumonia.
Material and methods: We conducted a prospective phase I-II trial enrolling COVID-19 patients ≥50 years-old, with bilateral lung involvement at imaging study and oxygen requirement (oxygen saturation ≤93% on room air). Patients received 1 Gy to whole lungs in a single fraction. Primary outcome was a radiological response assessed as severity and extension scores at days +3 and +7. Secondary outcomes were toxicity (CTCAE v5.0), days of hospitalization, changes in inflammatory blood parameters (ferritin, lymphocytes, C-reactive protein, d-dimer and LDH) and SatO 2 /FiO 2 index (SAFI), at day +3 and +7. Descriptive analyses were summarized as means with standard deviation (SD) and/or medians with interquartile ranges (IQR). A Wilcoxon sign rank test for paired data was used to assess the CT scores and Chi Square was used to assess for comparison of categorical variables.
Results: Forty-one patients were included. Median age was 71 (IQR 60-84). Eighteen patients (44%) previously received an anti-COVID treatment (tocilizumab, lopinavir/ritonavir, remdesivir) and thirty-two patients (84%) received steroids during LD-RT. The extension score improved significantly (p = 0.02) on day +7. Mean baseline extension score was 13.7 (SD ± 4.9) with a score of 12.2 (±5.2) at day 3, and 12.4 ± 4.7 at day 7. No differences were found in the severity score. SAFI improved significantly on day +3 and +7 (p < 0.01). Median SAFI on day 0 was 147 (IQR 118-264), 230 (IQR 120-343) on day +3 and 293 (IQR 121-353) on day +7. Significant decrease was found in C-reactive protein on day +7 (p = 0.02) and in lymphocytes counts on day +3 and +7 (p = 0.02). The median number of days in hospital after RT was 11 (range 4-78). With a median follow-up of 60 days after LD-RT, 26 (63%) patients were discharged, 11 (27%) died because of COVID respiratory failure and 4 (10%) died of other causes.
Conclusions: LD-RT is a feasible and well-tolerated treatment that could lead to rapid clinical improvement. Large randomized trials would be required to establish the efficacy of LD-RT to treat COVID-19 pneumonia.
Keywords: Benign disease; COVID-19; LD-RT; Pneumonia; Radiation.
【저자키워드】 COVID-19, Pneumonia, Benign disease, LD-RT, Radiation., Radiation, 【초록키워드】 Treatment, Efficacy, Lymphocytes, Respiratory failure, Trial, Hospitalization, Tocilizumab, severity, lung involvement, hospital, randomized trial, Remdesivir, lung, LDH, C-reactive protein, ferritin, Toxicity, outcome, COVID, lymphocyte, oxygen saturation, management, low-dose, Patient, Clinical improvement, age, Follow-up, Blood, radiation therapy, Inflammatory, COVID-19 patient, steroid, interquartile range, Standard deviation, causes, SAFI, treat, fraction, material, extension, Oxygen requirement, parameter, secondary, decrease, radiological, square, CTCAE, was used, evaluate, died, significantly, required, conducted, median, changes in, feasible, discharged, Significant, baseline, Benign, Descriptive analysis, IQR, patients with COVID-19, variables, 【제목키워드】 Trial,